

Once-Daily Maraviroc in Treatment-Naïve
A4001078 Trial

Once-Daily Maraviroc plus Ritonavir-Boosted Atazanavir A4001078: Study Design

Study Design: A4001078 Study

- **Background:** Phase 2b, randomized, open label pilot study evaluating a once-daily, dual-therapy regimen of maraviroc and boosted atazanavir in comparison to standard triple therapy in HIV-infected treatment-naïve patients
- **Inclusion Criteria (n = 121)**
 - Age \geq 16
 - Antiretroviral-naïve patients
 - R-5 tropic virus
 - HIV RNA \geq 1000 copies/mL
 - CD4 \geq 100 cells/mm³
- **Treatment Arms** (all medications once daily)
 - Maraviroc 150 mg +
Atazanavir 300 mg + Ritonavir 100 mg
 - Tenofovir DF-Emtricitabine +
Atazanavir 300 mg + Ritonavir 100 mg

**Maraviroc QD +
Atazanavir + Ritonavir**


(n = 60)

**Tenofovir DF-Emtricitabine
+ Atazanavir + Ritonavir**

(n = 61)

Once-Daily Maraviroc plus Ritonavir-Boosted Atazanavir A4001078: Results

Week 48: Virologic Response (Missing or Discontinued = Failure)



Once-Daily Maraviroc plus Ritonavir-Boosted Atazanavir A4001078: Conclusions

Conclusions: “The virological activity and immunological benefit of once-daily MVC + ATV/r were confirmed. Indirect hyperbilirubinemia and associated signs were the most commonly reported adverse effects in both study treatment groups and were not associated with significant transaminase increases. No drug resistance occurred.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

